BUSINESS● LOWSep 14 · Sep 14, 2026, 10:54 AM
Tyra Biosciences prices $400 million equity offering to fund dabogratinib development and other programs
Seeking Alpha Tech · global
Tyra Biosciences has priced a $400 million equity offering to finance the development of dabogratinib and other programs. This represents a significant capital raise for the company.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS28m agoScary deals? What makes Hong Kong shun death-linked homes while France embraces the riskSouth China Morning PostBUSINESS49m agoIn 1984, Patrick Swayze bought a 4.5-acre ranch on the outskirts of Los Angeles and converted it into a refuge for Arabian horses with an 11-stall stable, a riding arena, and a dance studio; after his death, it sold for $2.9 million and was later put up for sale againClarín